Dec 4 (Reuters) - Roche Holding AG:
* NEW VENCLEXTA/VENCLYXTO DATA DEMONSTRATE DEEP RESPONSES IN TWO OF MOST COMMON TYPES OF LEUKAEMIA
* NEW ANALYSES FROM PHASE III MURANO STUDY IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKAEMIA SHOW CONTINUED BENEFIT FROM FIXED-DURATION REGIMEN AFTER A MEDIAN FOLLOW-UP OF THREE YEARS
* UPDATED RESULTS FROM TWO STUDIES IN NEWLY-DIAGNOSED ACUTE MYELOID LEUKAEMIA DEMONSTRATE VENCLEXTA COMBINATIONS CONTINUED HIGH RATES OF DEEP REMISSION Source text for Eikon: Further company coverage: (Reporting by Riham Alkousaa)
